Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2017, Vol. 44 Issue (2): 203-207    DOI: 10.12891/ceog3262.2017
Original Research Previous articles | Next articles
Analysis of bromocriptine treatment in pregnant pituitary prolactinoma patients
W. Lian1, *(), N. Liu2, R.Z. Wang1, B. Xing1, Y. Yao1
1 Department of Neurosurgery, Peking Union Medical College Hospital, Beijing Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China
2 Department of Neurosurgery, The Second Affiliated Hospital, Shandong University of Traditional Chinese Medicine, Jinan, China
Download:  PDF
Export:  BibTeX | EndNote (RIS)      
Abstract  
Objective: To investigate the therapeutic effects and duration of bromocriptine treatment during pregnancy in patients with pituitary prolactinoma. Materials and Methods: A retrospective analysis of the clinical data of 230 female pituitary prolactinoma patients at the Beijing Union Medical College Hospital neurosurgery clinic from January 2001 to May 2014 was conducted. When confirmed pregnant, patients in the control group immediately stopped taking bromocriptine, but patients in the treatment group continued to take the same dose of bromocriptine. Results: The embryos stop rate in the control group was 16.7%, significantly higher than the rate in the natural population (p < 0.05), while the rate in the treatment group (0.9%) not statistically different from that of the natural population (p > 0.05). There was no significant difference in the embryonic malformation rate between the two study groups compared to the normal pregnancy group (p > 0.05). Conclusion: Pregnant pituitary prolactinoma patients should not stop bromocriptine treatment, but should instead continue with the same dose for four months. For patients with macroadenoma, bromocriptine should be taken during the entire pregnancy. Blood prolactin, progesterone, human chorionic gonadotropin (hCG), and visual dysfunction should be monitored every two weeks during treatment. Patients should be treated with progesterone and hCG if the blood levels become too low. If regular monitoring shows that prolactin has increased too fast and/or visual dysfunction worsened, the dose of bromocriptine should be increased. The authors have found that bromocriptine treatment during pregnancy significantly reduces the embryo stop rate without increasing the embryo deformity rate; therefore, bromocriptine treatment is safe and necessary during pregnancy of pituitary prolactinoma patients.
Key words:  Pituitary adenoma      Prolactin      Pregnancy      Bromocriptine     
Published:  10 April 2017     
*Corresponding Author(s):  W. LIAN     E-mail:  weilian996@163.com

Cite this article: 

W. Lian, N. Liu, R.Z. Wang, B. Xing, Y. Yao. Analysis of bromocriptine treatment in pregnant pituitary prolactinoma patients. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(2): 203-207.

URL: 

https://ceog.imrpress.com/EN/10.12891/ceog3262.2017     OR     https://ceog.imrpress.com/EN/Y2017/V44/I2/203

[1] H. Yolli, M.E. Demir, R. Yildizhan. Neutrophil gelatinase associated lipocalin-2 (Ngal) levels in preeclampsia[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 519-523.
[2] K. Chikazawa, K. Imai, T. Kuwata, K. Takagi. Prophylactic laparoscopic adnexal surgery with low-pressure CO2 insufflation for ovarian cysts during the late first trimester or second trimester of pregnancy[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 537-540.
[3] J. A. Villarreal-Rodriguez, L. G. Mancillas Adame, J. Maldonado-Sanchez, A. Guzmán-López, O. R. Treviño-Montemayor, J. G. Gonzalez-Gonzalez, D. Saldívar-Rodríguez. A randomized controlled trial comparing acarbose vs. insulin therapy for gestational diabetes in individuals with inadequate glycemic control by diet alone[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 552-555.
[4] J. Ogawa, S. Suzuki. Risk factors of self-interruption of medications for mental disorders in pregnancy[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 576-578.
[5] A. Daniilidis, G. Dryllis, G. Chorozoglou, M. Politou, R. Dampali, K. Dinas. Substitution of hemoglobin levels in pregnant women with iron supplement: A prospective randomized clinical study[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 579-583.
[6] Z.Y. Chang, R. Cao, R.C. Xu, Y. Cheng, Q.J. Wan. Pregnancy in a peritoneal dialysis patient undergoing intermittent peritoneal dialysis during the third trimester of pregnancy: a case report and literature review[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 596-599.
[7] C.Y. Huang, T.C. Chao, H.C. Chien, Y.L. Liu. Outcome of shared decision-making in a patient with primary herpes gingivostomatitis during pregnancy: a case report[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 604-606.
[8] G.L. Liu, S.C. He, W.J. Shan, H.Y. Chen. Repetitive hydatidiform mole in the cesarean scar: a case report and literature review[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 607-610.
[9] K. Nakanishi, Y. Oishi, T. Miyamoto, E. Nakamura, K. Murakami, M. Ono, A. Nozawa, S. Kitamura, K. Sengoku. Anti-E alloimmunization in a pregnancy with a low antibody titer[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 614-616.
[10] F. Wang, Z.X. Liang, W.R. Mao, S.N. He, D.Q. Chen. Influence of pre-pregnancy body mass index and gestational weight gain in twin pregnancies on blood glucose, serum lipid and perinatal outcomes[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(3): 376-382.
[11] G. Keren, G. Ayala. Factors associated with hyperemesis gravidarum[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(3): 391-395.
[12] H. Cokmez, C. Bayram. Pituitary apoplexy developing during pregnancy: escape from the verge of death[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(3): 429-431.
[13] H.J. Wang, T.H. Chou, Y.C. Lee, H.K. Au. Acute fatty liver during pregnancy and gestational diabetes insipidus: a case report[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(3): 438-441.
[14] Y.Q. Xu, X. L. Chen, S. Zhao, P. W. Chen, X. M. Yin, S. Y. Xiong, Z. Ding, F. Xiong, X. H. Yang. OEIS complex (omphalocele-exstrophy-imperforate anus-spinal defects) in monozygotic twins: a case report and literature review[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(2): 154-158.
[15] H.F. Zhang, J. Zhang, D. Yang, S.N. Li. Clinical analysis of atrial fibrillation in pregnant women[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(2): 174-178.
No Suggested Reading articles found!